Papers

---

Eprinomectin: a derivative of Ivermectin SUPPRESSES GROWTH AND METASTATIC PHENOTYPES OF PROSTATE CANCER cells by targeting the β-catenin signaling pathway

• https://link.springer.com/article/10.1007/s00432-023-04829-5

___• https://archive.md/Ycxty

___• https://web.archive.org/web/20231008143657/https://link.springer.com/article/10.1007/s00432-023-04829-5

• Author: Angela Samy, Mohamed Ali Hussein, Gnanasekar Munirathinam

---

Ivermectin SUPPRESSES PANCREATIC CANCER via mitochondria dysfunction

• https://aacrjournals.org/cancerres/article/82/12_Supplement/2320/701043

___• https://archive.md/4EaJG

___• https://web.archive.org/web/20231008143718/https://aacrjournals.org/cancerres/article/82/12_Supplement/2320/701043

• Author: Daeun Lee, Joon Seong Park, Yun Sun Lee

---

Ivermectin has New Application in INHIBITING COLORECTAL CANCER Cell Growth

• https://www.frontiersin.org/articles/10.3389/fphar.2021.717529/full

___• https://archive.li/Fn3aE

___• https://web.archive.org/web/20230720061933/https://www.frontiersin.org/articles/10.3389/fphar.2021.717529/full

• Author: Shican Zhou, Hang Wu, Wenjuan Ning

---

Anti-parasitic Drug Ivermectin Exhibits POTENT ANTICANCER ACTIVITY Against Gemcitabine-resistant Cholangiocarcinoma In Vitro

• https://ar.iiarjournals.org/content/39/9/4837.full

___• https://archive.md/pPxW9

___• https://web.archive.org/web/20231003152611/https://ar.iiarjournals.org/content/39/9/4837.full

• Author: Kitti Intuyod, Chariya Hahnvajanawong, Porntip Pinlaor

---

NIH: Ivermectin, a POTENTIAL ANTICANCER DRUG derived from an antiparasitic drug

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/

___• https://archive.md/S9QuS

___• https://web.archive.org/web/20230831120431/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/

• Author: Mingyang Tang, Xiaodong Hu, Yi Wang

• Video à https://www.bitchute.com/video/NadONSYKjQKU/

___• https://web.archive.org/web/20230708221126/https://www.bitchute.com/video/NadONSYKjQKU/

---

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in LUNG ADENOCARCINOMA CELLS

• https://link.springer.com/article/10.1007/s00280-023-04589-6

___• https://archive.md/Zavbu

___• https://web.archive.org/web/20231008143739/https://link.springer.com/article/10.1007/s00280-023-04589-6

• Author: Man-Yuan Li, Jiao Zhang, Xiao Lu

---

The ANTICANCER POTENTIAL OF IVERMECTIN: Mechanisms of Action and Therapeutic Implications

• https://jlar.rovedar.com/index.php/JLAR/article/view/11

___• https://archive.md/n4304

___• https://web.archive.org/web/20230803124614/https://jlar.rovedar.com/index.php/JLAR/article/view/11

• Author: Narges Lotfalizadeh, Arian Gharib, Ashkan Hajjafari

---

Progress in Understanding the Molecular Mechanisms Underlying the ANTITUMOUR EFFECTS OF IVERMECTIN

• https://www.tandfonline.com/doi/full/10.2147/DDDT.S237393

___• https://archive.md/kUoep

___• https://web.archive.org/web/20230000000000*/https://www.tandfonline.com/doi/full/10.2147/DDDT.S237393

• Author: Jian Liu, Kun Zhang, Lin Cheng

---

The multitargeted drug ivermectin: from an antiparasitic agent to A REPOSITIONED CANCER DRUG

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/

___• https://archive.md/tW2zF

___• https://web.archive.org/web/20231008143705/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/

• Author: Mandy Juarez, Alejandro Schcolnik-Cabrera, Alfonso Dueñas-Gonzalez

---

---

Source

Dr. William Makis. In his "COVID Intel" publication at https://makismd.substack.com/p/ivermectin-and-cancer-it-has-at-least/comments

This publication above is visible only to his paid subscribers

I do not have a conflict of interest with any of the above

---

Disclaimer

This blog is about expressing my opinions, feelings, and thoughts. Nothing else. In other words, but not limited to, my blog is NOT a recommendation, NOT an advice, NOT a call for violence to self or others, NOT an endorsement. If you need recommendation of any kind, such as but not limited to, medical or legal recommendation, I suggest considering asking an appropriate professional to your liking. I suggest choosing one without conflict of interest.